Evaluation of Heterozygous Deletion of TP53 Gene in Pleural Fluid Samples: A Case Series of 11 Patients


Creative Commons License

Dirican N., Bagci O., Uz E., ÖZTÜRK Ö., BİRCAN H. A., Dirican A.

JOURNAL OF CLINICAL AND ANALYTICAL MEDICINE, vol.7, pp.165-167, 2016 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 7
  • Publication Date: 2016
  • Doi Number: 10.4328/jcam.4551
  • Journal Name: JOURNAL OF CLINICAL AND ANALYTICAL MEDICINE
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.165-167
  • Keywords: Pleural Effusion, Malignancy, TP53 Gene, IN-SITU HYBRIDIZATION, CANCER, CHROMOSOME-9, MECHANISMS, EFFUSIONS, FREQUENCY, ANTIGEN, MARKER, TUMORS, FISH
  • Bezmialem Vakıf University Affiliated: No

Abstract

We described heterozygous deletion of tumor protein 53 (TP53) gene in 11 patients including 2 patients with non- malignant diseases (pneumonia) and 9 patients with malignant diseases [including small cell lung cancer (n = 3), non-small cell lung carcinoma (n = 4), non-Hodgkin's lymphoma (n= 1), and gastric carcinoma (n= 1)]. Chromosomal aberrant status was analyzed by fluorescence in situ hybridization with centromere specific and 17p13.1 locus specific probes. In 3 of 9 cancer patients we did not find malignant pleural effusion with histological examination and/or closed pleural biopsy. Heterozygous deletion of TP53 gene was found to be significantly higher in patients with malignant disease when compared to the patients with benign pleural fluid. As a result, we suggest that heterozygous deletion of TP53 may have indicator value for malignancy; however further studies are warranted to confirm this suggestion in large patient cohorts.